breaking

Lilly's Oral Obesity Drug Gains Momentum in Physician Surveys

Eli Lilly's oral GLP-1 medication is gaining traction among physicians, according to new data released Tuesday. Citigroup's survey of doctors prescribing oral weight-loss drugs found that approximately half expect these medications to attract new patients to the category. The analysis also revealed many patients previously using injectable versions are switching to pill formulations. Lilly's Foundayo continues to capture prescriptions from patients without prior GLP-1 experience, with roughly 80 percent of prescriptions going to those who previously weren't taking a GLP-1. The oral obesity drug market remains competitive, with Novo Nordisk's Wegovy pill as the primary rival. Analysts expect Foundayo to gain share over time despite Wegovy's early launch success and brand recognition advantage. Lilly shares climbed more than 2 percent following the positive findings.